Xiaojun Sun

Xiaojun Sun

Auto-generated profile, based on publicly available information

Xiaojun Sun

Taizhou Hospital of Chinese Traditional Medicine, Multidisciplinary Center, Taizhou, Jiangsu 225300, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SYShigao Yang
Shigao Yang
YWYinyin Wang
Yinyin Wang
KMKunrong Mei
Kunrong Mei
SZSen Zhang
Sen Zhang
XSXiaojun Sun
Xiaojun Sun
ZCZhijie Chang
Zhijie Chang
TNF receptor 2 (TNFR2) exerts diverse roles in the pathogenesis of inflammatory and autoimmune diseases. Here, we report that TNFR2 but not TNFR1 forms a heteromer with interleukin-17 receptor D (IL-17RD), also named Sef, to activate NF-κB signaling. TNFR2 associates with IL-17RD, leading to mutual receptor aggregation and TRAF2 recruitment, which further activate the downstream cascade of NF-κB signaling. Depletion of IL-17RD impaired TNFR2-mediated activation of NF-κB signaling. Importantly, IL-17RD was markedly increased in renal tubular epithelial cells in nephritis rats, and a strong interaction of TNFR2 and IL-17RD was observed in the renal epithelia. The IL-17RD·TNFR2 complex in activation of NF-κB may explain the role of TNFR2 in inflammatory diseases including nephritis.

1 October 2013 in Cellular Signalling
Verified
Journal Article
Closed access
XSXiaojun Sun
Xiaojun Sun
YWYinyin Wang
Yinyin Wang
SYShigao Yang
Shigao Yang
FRFangli Ren
Fangli Ren
YXYongjing Xia
Yongjing Xia
ZCZhijie Chang
Zhijie Chang

17 December 2020 in Infectious Diseases in Obstetrics and Gynecology
Verified
Journal Article
Open access
PDF file
XSXiaojun Sun
Xiaojun Sun
CWChengwei Wang
Chengwei Wang
BWBian Wang
Bian Wang
XYXiuzhen Yang
Xiuzhen Yang
HXHongtao Xu
Hongtao Xu
KZKuichun Zhu
Kuichun Zhu
The objective of this study was to investigate the efficacy and potential side-effects of nucleotide/nucleoside analogues and hepatitis B immunoglobulin injection of newborns in blocking mother-to-child transmission of hepatitis B virus in the middle and late pregnancy period. 238 cases of enrolled pregnant women were divided into the Telbivudine group, the Tenofovir group, the Lamivudine group, and the hepatitis B immunoglobulin (HBIG) group. Enrolled patients received corresponding therapies. Clinical and laboratory data were collected. Results showed that the levels of HBV DNA of the enrolled pregnant women in the Telbivudine, Tenofovir, and Lamivudine groups decreased rapidly after 12 weeks of drug intervention compared with those in the control. HBsAg positive rate in newborns and in children 24 weeks after birth was 0/60, 0/60, 0/60, 3/30, and 11/28 in the Telbivudine, Tenofovir, Lamivudine, HBIG, and control groups, respectively. No significant side-effects were identified after following up to 12 months after birth. Our results show that routine HBV vaccine plus HBIG injections is insufficient in blocking mother-to-child HBV transmission. Administration of nucleotide/nucleoside analogues or HBIG at pregnancy is suggested to maximize the blocking of vertical HBV transmission.

1 October 2011
Verified
Journal Article
Closed access
XSXiaojun Sun
Xiaojun Sun
KMKunrong Mei
Kunrong Mei
YWYinyin Wang
Yinyin Wang
FRFangli Ren
Fangli Ren
YXYongjing Xia
Yongjing Xia
ZCZhijie Chang
Zhijie Chang